GlassScriptPhysician profile
Sterling Nicole Kosmach
NPI 1952713489
$6,536.57
in general payments reported to CMS, 2019-2025
20 companies · $3,383 in 2025
The $3,383 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.74 · 2023: $1,652 · 2024: $1,476 · 2025: $3,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,600 · Consulting Fee: $1,812 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,599.83 |
| Consulting Fee | $1,812.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $1,812.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,657.45 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,079.14 | 2023-2025 | |
| Pharming Healthcare, INC. | $476.60 | 2022-2024 | Joenja, Ruconest |
| Regeneron Healthcare Solutions, INC. | $230.07 | 2024-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $172.18 | 2023-2025 | Orladeyo |
| Genentech, INC. | $145.98 | 2025 | Xolair |
| Csl Behring | $133.55 | 2023-2024 | Hizentra |
| Novartis Pharmaceuticals Corporation | $133.15 | 2024-2025 | |
| Blueprint Medicines Corporation | $110.48 | 2024-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Glaxosmithkline, LLC. | $96.48 | 2023-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $87.67 | 2023-2025 | Takhzyro, Eohilia |
| Amgen INC. | $75.33 | 2024-2025 | Tezspire |
| Genentech USA, INC. | $71.75 | 2024-2025 | Xolair |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $51.44 | 2025 | Sajazir |
| Incyte Corporation | $43.41 | 2024-2025 | Opzelura |
| Kaleo, INC. | $27.58 | 2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $22.78 | 2025 | Neffy |
| Organon LLC | $10.53 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sterling Kosmach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.